Inhibrx Biosciences (INBX)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from INBX's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Inhibrx Biosciences's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $2M | $200,000 | $1M |
| Net income | -$241M | $1.7B | -$140M |
| Free cash flow | -$198M | -$197M | -$130M |
| EPS (diluted) | -$20.48 | $112.62 | -$9.04 |
| Operating margin | -12178.9% | -165724.0% | -10386.5% |
Superinvestors who own INBX
From each investor's latest 13F filing (what a 13F shows). 2 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Andreas Halvorsen Viking Global Investors |
Trimmed | $106M | 0.30% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | $1M | 0.0% | Q2 2026 |
Insider buying
Open-market purchases by Inhibrx Biosciences's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you. Every purchase since records began.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Sep 28, 2026 | Mark Lappe Chief Executive Officer |
1,500 | $98.88 | $148,320 |
| Sep 28, 2026 | Mark Lappe Chief Executive Officer |
3,000 | $101.70 | $305,106 |
| Sep 25, 2026 | Mark Lappe Chief Executive Officer |
3,324 | $98.87 | $328,630 |
| Sep 25, 2026 | Mark Lappe Chief Executive Officer |
2,176 | $99.60 | $216,727 |
| Sep 23, 2026 | Jon Faiz Kayyem Director |
5,000 | $100.00 | $500,000 |
| Sep 16, 2026 | Jon Faiz Kayyem Director |
5,000 | $100.00 | $500,000 |
| Sep 8, 2026 | Mark Lappe Chief Executive Officer |
9,681 | $112.28 | $1M |
| Sep 8, 2026 | Douglas Forsyth Director |
2,500 | $114.65 | $286,617 |
| Sep 8, 2026 | Jon Faiz Kayyem Director |
5,000 | $113.52 | $567,580 |
| Sep 8, 2026 | Mark Lappe Chief Executive Officer |
5,895 | $99.29 | $585,343 |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when INBX trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Inhibrx Biosciences insiders buying the stock?
10 open-market insider purchases of INBX in the last 12 months, from SEC Form 4 filings.
Which superinvestors own Inhibrx Biosciences?
2 of the superinvestors Investingly tracks hold INBX in their latest 13F, including Andreas Halvorsen, Cliff Asness.
Companies like Inhibrx Biosciences
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.